A Bidirectional Conversion Treatment for Gastric Cancer with Peritoneal Metastasis: a Prospective Phase II Clinical Research

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17013305

Enrollment

Unknown

Registered

2017-11-08

Start date

2018-01-01

Completion date

Unknown

Last updated

2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal carcinomatosis from gastric cancer

Interventions

Group A:HIPEC+NIPEC+Post-operative SOX+Post-operative Apatinib

Group B:HIPEC+NIPEC+Post-operative SOX

Group C:Only Post-operative SOX

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 20-75 years old; 2. Karnofsky performance status score over 50; 3. free cancer cells tested positive; 4. the peritoneal metastasis was supported by serology, imaging and laparoscopy; 5. biopsy confirmed gastric cancer peritoneal metastasis.

Exclusion criteria

Exclusion criteria: 1. any lung metastasis, liver metastasis or prominent retroperitoneal lymph node metastasis during preoperative workup; 2. small mesenteric severe contracture; 3. severe adhesions in peritoneal cavity; 4. conventional surgical contraindications.

Design outcomes

Primary

Measure	Time frame
PCI score differences;Conversion success rate;the rate CC0/1 after Conversion by CRS;	—

Secondary

Measure	Time frame
disease-specific survival;overall survival;disease-free survival;overall response rate;time to progress;independent prognostic factor;	—

Countries

China

Contacts

Public ContactBin Xiong

Zhongnan Hospital of Wuhan University

binxiong1961@163.com+86 027-67813152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026